STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2482 by analyst upside · 2026-06-27
MIRM
Mirum Pharmaceuticals, Inc.
Healthcare · Market Cap $8B · P/E 0x
ANALYST PRICE TARGET
+17.4%
implied upside to consensus target
Current Price $123.77
Consensus Target $145.36
Bull Target $185.0
Bear Target $115.0
Analysts Covering 14
ANALYST CONSENSUS - BUY
Strong Buy
4
Buy
10
Hold
0
Sell
0
52-Week Low $47.89
52-Week High $124.43
YTD Return +58.5%
FUNDAMENTALS
Market Cap $8B
P/E Ratio (TTM) N/A
Forward P/E -1414.5x
EPS (TTM) $-13.60
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $570M
Profit Margin -140.2%
52-WEEK RANGE
52-Week Low $47.89
52-Week High $124.43
Current Price $123.77
Bear Target $115.0
Bull Target $185.0
● Now $123.77 ● Target $145.36
TRADING DATA
Avg Volume 980K
YTD Return +58.5%
Analyst Count 14
Consensus Buy
Upside to Target +17.4%
Last Updated 2026-06-27

ANALYST SUMMARY

Mirum Pharmaceuticals, Inc. (MIRM) is currently trading at $123.77 with a Wall Street consensus price target of $145.36, implying potential upside of 17.4% over the next 12 months. 14 analysts currently cover MIRM, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $185.0, while the most cautious has a target of $115.0.

MIRM operates in the Healthcare sector with a market capitalisation of $8B. The stock is up 58.5% year-to-date and is currently trading near the upper end of its 52-week range of $47.89 – $124.43.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for MIRM, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Citizens — Reiterated
Market Outperform → Market Outperform 2026-06-15 Building track record
Morgan Stanley — Reiterated
Overweight → Overweight 2026-06-11 Building track record
Citigroup ● Initiated
Buy 2026-06-02 Building track record
Wolfe Research ● Initiated
Outperform 2026-05-19 Building track record
TD Cowen — Reiterated
Buy → Buy 2026-05-07 Building track record
RBC Capital — Reiterated
Outperform → Outperform 2026-05-07 Building track record
Evercore ISI Group — Reiterated
Outperform → Outperform 2026-05-07 Building track record
Baird — Reiterated
Outperform → Outperform 2026-05-07 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
67
out of 100
Coverage depth
21/30
Consensus clarity
19/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →